The DE019 ( methotrexate [ MTX ] - inadequate responders , longstanding RA ) and PREMIER ( MTX-naive , early RA ) studies , respectively , had 1 - or 2-year double-blind periods followed by 9 - or 8-year open-label extensions ( OLEs ) .